Genomic Tests Improve Prediction of Breast Cancer Response to Chemotherapy

Armen Hareyan's picture
Advertisement

Breast Cancer Response to Chemotherapy

Researchers at The University of Texas M. D. Anderson Cancer Center have developed two genomic tests to better predict how breast cancer patients will respond to chemotherapy or hormonal therapy.

Advertisement

In presentations Dec. 14-15 at the San Antonio Breast Cancer Symposium, the research team reports on a highly sensitive multiple-gene test designed to predict response to chemotherapy, performed before surgery at M. D. Anderson, and a genomic index that gauges 10-year survival for patients who receive post-operative hormonal therapy with the drug tamoxifen.

"We are moving these tests toward clinical trials, where we can measure improvements in treatment response and track how physicians and patients use this information to make better decisions about treatment," says one of the team leaders,

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement